AI Article Synopsis
- MERS-CoV, discovered in 2012, has led to over 1,800 infections and 650 deaths, with no current approved treatments or vaccines.
- The spike (S) protein of MERS-CoV is crucial for infection and is a promising target for vaccine development since it stimulates the immune response.
- The study shows that a recombinant MERS-CoV S nanoparticle vaccine combined with the Matrix-M1 adjuvant effectively induced strong antibody responses and protected mice from the virus.
Article Abstract
The Middle East respiratory syndrome coronavirus (MERS-CoV) was first discovered in late 2012 and has gone on to cause over 1800 infections and 650 deaths. There are currently no approved therapeutics or vaccinations for MERS-CoV. The MERS-CoV spike (S) protein is responsible for receptor binding and virion entry to cells, is immunodominant and induces neutralizing antibodies in vivo, all of which, make the S protein an ideal target for anti-MERS-CoV vaccines. In this study, we demonstrate protection induced by vaccination with a recombinant MERS-CoV S nanoparticle vaccine and Matrix-M1 adjuvant combination in mice. The MERS-CoV S nanoparticle vaccine produced high titer anti-S neutralizing antibody and protected mice from MERS-CoV infection in vivo.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423355 | PMC |
| http://dx.doi.org/10.1016/j.vaccine.2017.02.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!